Kamada Ltd. (KMDA)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 180,460,000 12.1%
- Net income
- 20,198,000 39.7%
- Gross profit
- 76,407,000
- Operating income
- 26,233,000
- Earnings per share
- 0.35 40%
- R&D expense
- 12,995,000
Growth and profitability
- Gross margin
- 42.34
- Operating margin
- 14.54
- Net margin
- 11.19
- Return on equity
- 7.51
- Return on assets
- 5.33
Balance sheet
- Total assets
- 378,710,000
- Shareholders' equity
- 269,070,000
- Cash and equivalents
- 75,469,000
- Current ratio
- 4.07
Cash flow and ratios
- Operating cash flow
- 25,490,000
- Interest coverage
- 30.36
Shareholder returns
- Dividends paid
- 11,534,000
- Shares outstanding
- 57,686,056
- Book value per share
- 4.66
Company information
- Headquarters
- Rehovot, L3
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Kamada Ltd. trades on NASDAQ under the ticker symbol KMDA. This page brings together its price chart, company profile, key financial figures and technical indicators.